About Revolution Medicines, Inc. - Common Stock (RVMD)
Revolution Medicines Inc is a biotechnology company focused on developing innovative therapies to target difficult-to-treat cancers. The company is dedicated to advancing the field of precision medicine, leveraging its proprietary drug discovery platforms to explore new approaches to inhibit cancer-causing pathways. Through rigorous research and clinical trials, Revolution Medicines aims to bring forward novel treatments that not only address the complexities of tumor biology but also improve the effectiveness and safety of cancer care for patients. Their commitment to scientific excellence and collaboration positions them as a forward-thinking leader in the oncology space. Read More
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. Daraxonrasib taken orally once daily demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard of care cytotoxic chemotherapy delivered intravenously. In the overall (intent-to-treat) study population, daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise spending and payments.
